Skip to main content

Table 1 Characteristics of never- and ever-smokers included in the current study

From: Limited overlap in significant hits between genome-wide association studies on two airflow obstruction definitions in the same population

 

Never-smokers

Ever-smokers

LifeLines

Vla-Vlab

RS I

RS II

RS III

LifeLines

Vla-Vlab

RS I

RS II

RS III

N with no missing data

5070

432

408

379

747

4855

823

640

583

1088

Males, N (%)

1942 (38)

103 (23)

81 (20)

124 (33)

308 (41)

2312 (48)

590 (72)

375 (59)

343 (59)

531 (49)

Age (yrs), median (min-max)

46 (18–89)

54 (36–79)

78 (72–94)

71 (65–98)

62 (51–93)

49 (22–85)

53 (35–79)

79 (72–95)

71 (65–93)

62 (52–93)

Height (cm), mean (SD)

174 (9)

166 (9)

163 (9)

166 (9)

171 (9)

175 (9)

173 (8)

168 (9)

171 (9)

172 (9)

Current-smokers, N (%)

–

–

–

–

–

2171 (45)

478 (58)

99 (16)

108 (19)

298 (27)

Pack-years (yrs), mean (SD)

–

–

–

–

–

17 (11)

27 (21)

29 (21)

29 (21)

27 (20)

Pulmonary function, mean (SD)

 FEV1%predicted (%), mean (SD)a

98 (13)

91 (13)

101 (18)

102 (16)

101 (16)

94 (14)

85 (15)

98 (23)

96 (21)

99 (19)

 FEV1/FVC (%), mean (SD)b

78 (7)

76 (7)

77 (7)

79 (6)

78 (6)

75 (8)

72 (10)

74 (9)

74 (9)

75 (8)

 FEV1/FVC <70%, N (%)

548 (11)

77 (18)

51 (13)

27 (7)

75 (10)

1107 (23)

287 (35)

163 (26)

151 (26)

235 (22)

 FEV1/FVC < LLN, N (%)

401 (8)

49 (11)

9 (2)

9 (2)

25 (3)

833 (17)

212 (26)

63 (10)

62 (11)

122 (11)

 Both FEV1/FVC <70% and < LLN, N (%)

371 (7)

49 (11)

9 (2)

9 (2)

25 (3)

802 (17)

207 (25)

63 (10)

62 (11)

122 (11)

Moderate/severe COPD, N (%)c

106 (2)

26 (6)

21 (5)

9 (2)

16 (2)

310 (6)

145 (18)

90 (14)

90 (15)

104 (10)

  1. Discovery sample = LifeLines cohort study, replication samples = Vlagtwedde-Vlaardingen (Vla-Vla) study, and SNP validation sample = Vla-Vla and RS I to III
  2. FEV1 forced expiratory volume in one second, FVC forced vital capacity
  3. aFEV1%predicted is based on the reference equation by GLI-2012 [21]
  4. bFEV1%IVC (inspiratory vital capacity) for the Vlagtwedde-Vlaardingen study (Vla-Vla)
  5. cCOPD GOLD stage 2 and up (FEV1/FVC <70% and FEV1%p < 80% based on pre-bronchodilator measurements)